TKG (formerly Taekwang Industrial Group) and IMM Investment will acquire KOSDAQ-listed biotech firm AprilBio.
On the 24th, according to the investment banking (IB) industry and the biotech industry, the two companies decided to participate in AprilBio's third-party paid-in capital increase. TKG will take the lead, with IMM Investment participating as a financial investor (FI).
IMM Investment will participate in the equity acquisition together with its affiliated manager, IMM Asset Management. According to Financial Supervisory Service electronic disclosures, they decided to invest a total of 141.7 billion won. The new share issue price is 34,620 won.
※ This article has been translated by AI. Share your feedback here.